Navigation Links
Man against HIV – new vaccine ready for human trials

A new vaccine called the TAT vaccine has been developed in Italy as the latest and most exciting HIV vaccine to date. And more importantly it has had a 71% success rate when tested on monkeys. This vaccine is now ready for human testing and this may be the brightest hope for mankind against the destructive HIV.

Dr.Barbara Ensoli, Head of the Department of Virology at Italy’s National Health Institute and Dr.Robert Gallo, one of the fathers of AIDS research have developed this vaccine which promises to be a strong salvo against the human immunodeficiency virus.

This project has consumed five years of dedicated work and employs an entirely new approach in tackling the virus. The idea is to block the virus from growing inside the body rather than trying to bolster the immune system against the virus as many vaccines try to do.

TAT protein is an important protein in the virus, which is a key building block of the dreaded virus. By blocking the TAT protein the scientists hope to stop the growth of the virus inside the human body. So they say this vaccine will be effective even in old cases of HIV. All eyes are now on the results of human testing of this vaccine to see how effective this could be.

The ability of the virus to mutate and survive has made it smart and strong to survive all the initiatives man has taken to eliminate it. The TAT vaccine is the latest hope for man against the virus! Lets hope this works!!
'"/>




Page: 1

Related medicine news :

1. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
2. Antibiotics losing their power against acne
3. South Africa Wins landmark case against pharmaceutical giants
4. Vitamin E, the latest warrior against diabetes
5. Acne may protect against infections
6. Fight against E.coli
7. Defence against free radicals
8. Progestin protects against ovarian cancer
9. Beverage protect against bladder cancer
10. Moderate alcohol consumption protects against dementia
11. Broccolis role against cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Man against HIV new vaccine ready for human trials

(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... aid in digestion help keep the intestinal lining intact. ... , could yield new therapies for inflammatory bowel disease ... The research involved the intestinal microbiome, which contains some ... promoting or preventing disease is a major emerging field ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... scientists implicates a new protein in obesity development and highlights ... resistance. Jorge Moscat, PhD, chair of UC,s ... ERK are involved in adipogeneis, (the development of adipocytes, or ... works together. The study is published online in ...
... , BOULDER, Colo. , ... of Functional Fitness on Walk the Talk ... Sam Iannetta , a champion powerlifter, tells—and shows—how ... healing injuries, whatever your fitness practice: yoga, cycling, ...
... SHANGHAI , Feb. 12 General Nutrition ... announced today that it, together with its parent company, has entered ... Bright Food (Group) Co., LTD (Bright Food). The partnership, to be ... market. Bright Food , a leading state-owned conglomerate in ...
... received male donors, plasma had worse outcomes, study found ... blood-banking industry discourages transfusing the blood product known as ... reaction in the recipients. , But now researchers have ... have advantages. , Plasma is the fluid in ...
... Touching down toe-first is less economical in humans, research shows , ... to walk heel-first than to walk on the balls of your ... Compared with heel-first walking, it takes 83 percent more energy to ... on the balls of your feet, according to the University of ...
... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ...
Cached Medicine News:Health News:Research highlights role of protein pair in obesity regulation 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:Restrictions on Plasma From Female Donors May Need Revisiting 2Health News:Heel-First Walking Conserves Energy 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 3Health News:HeartMath Announces the Release of Their New emWave Desktop Software 4
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. Wedbush Life ... Wednesday, August 13, 2014 at 9.10 a.m. Eastern Time ... York, NY Thursday, September 4, 2014 at 8.30 ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... , NEW YORK, Dec. 7 ... updated efficacy and safety data as well as new ... in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients ... "A Multicenter Phase 1/2 Study Evaluating the Safety and ...
... , ENGLEWOOD, Colo., Dec. 7 ... system, DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting ... patient safety and pharmacy efficiency through the management of ... easily into current pharmacy practice and techniques, while providing ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: